IR Center

Corporate Profile

Biovest International, Inc. is a pioneer the field of personalized cancer vaccines and markets its state-of-the-art hollow fiber bioreactors, as well as provides custom cell culture services, including contract manufacturing. The Company exited Chapter 11 reorganization on July 9, 2013, with new shares issued to secured and unsecured creditors. Shares of common stock, warrants and options that were outstanding prior to the effective date of Biovest’s Plan of Reorganization (July 9, 2013) have been cancelled and have ceased to trade or be recognized as an ownership interest in the Company.

For more information on the reorganized Biovest, please visit this link for latest SEC filing:

Press ReleasesMore >>
07/15/13Biovest International Completes Restructuring and Emerges from Reorganization with Dr. Carlos F. Santos Appointed as CEO Printer Friendly Version
03/07/13Biovest Files Recapitalization Plan to Strengthen Balance Sheet and Advance Commercialization Strategy for BiovaxID™ Cancer VaccinePrinter Friendly Version
12/04/12Biovest to Present BiovaxID™ Cancer Vaccine Update at Lymphoma Coalition Patient Advocacy Event prior to ASH MeetingPrinter Friendly Version
09/20/12Biovest Conducts Meeting with EMA Advancing Process to Seek EU Approval for Cancer VaccinePrinter Friendly Version
09/11/12Biovest Names Lymphoma Key Opinion Leader from MD Anderson Cancer Center to Scientific Advisory BoardPrinter Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Biovest International Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.


Personalized cancer vaccine targeting certain B-cell lymphomas

BVTI Research Report

OneMedPlace initiates research on Biovest and BiovaxID lymphoma cancer vaccine

Media Center

Biovest headlines, videos, webcasts and feature articles